Drug Repositioning as a Pharmaceutical Strategy: The Obvious Benefits are Real but Beware of Pitfalls That May be Less Apparent.

Authors

  • Andrew G. Reaume

DOI:

https://doi.org/10.5912/jcb1011

Abstract

For the last 15 years the drug discovery strategy referred to as “drug-repositioning” has been a recognized approach towards bringing new therapeutics to market and has continued to grow in popularity over this time frame.  Melior Discovery is a company with a founding mission centered on drug repositioning.  The author shares his perspective on lessons learned over 15 years of conducting drug repositioning efforts, complete with advantages and disadvantages that he has encountered using this approach and why, overall, this means of drug discovery provides a compelling business rationale.

Downloads

Published

2021-12-23

Issue

Vol. 26 No. 4 (2021): Vol. 26 No. 4 (2021)

Section

Articles

License

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.